Abstract
This study aimed to investigate the safety and feasibility of intracoronary injection of human umbilical cord mesenchymal stem cell to the very old patients with coronary chronic total occlusion. 15 consecutive patients received mesenchymal stem cells from human umbilical cord in epicardial coronary artery supplying collateral circulation. The patients were randomly allocated to low-dose 3x106, mid-dose 4x106 and high-dose 5x106 groups. 99mTc single photon emission computed tomography images were obtained at 12 and 24 months. During the 24 month study period, no cases of major cardiac adverse events were reported. None of the patients had coronary care unit admissionshospitalizationsfurther coronary revascularizationacute myocardial infarction and death. The patients had a significant reduction of the infarct size and a remarkable rise in left ventricular ejection fraction with respect to secondary outcomes. This study suggested that stem cell transplantation was safe and feasible. The cells can be utilized to improve in the degree of ischemic myocardium, decrease in the infarct size and rise in left ventricular ejection fraction.
Keywords: Chronic myocardial ischemia, elderly, human umbilical cord-derived mesenchymal stem cells, therapy.
Current Pharmaceutical Design
Title:Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion
Volume: 21 Issue: 11
Author(s): Xia Li, You-dong Hu, Yan Guo, Ying Chen, Dian-xuan Guo, Hua-lan Zhou, Feng-lin Zhang and Qing-na Zhao
Affiliation:
Keywords: Chronic myocardial ischemia, elderly, human umbilical cord-derived mesenchymal stem cells, therapy.
Abstract: This study aimed to investigate the safety and feasibility of intracoronary injection of human umbilical cord mesenchymal stem cell to the very old patients with coronary chronic total occlusion. 15 consecutive patients received mesenchymal stem cells from human umbilical cord in epicardial coronary artery supplying collateral circulation. The patients were randomly allocated to low-dose 3x106, mid-dose 4x106 and high-dose 5x106 groups. 99mTc single photon emission computed tomography images were obtained at 12 and 24 months. During the 24 month study period, no cases of major cardiac adverse events were reported. None of the patients had coronary care unit admissionshospitalizationsfurther coronary revascularizationacute myocardial infarction and death. The patients had a significant reduction of the infarct size and a remarkable rise in left ventricular ejection fraction with respect to secondary outcomes. This study suggested that stem cell transplantation was safe and feasible. The cells can be utilized to improve in the degree of ischemic myocardium, decrease in the infarct size and rise in left ventricular ejection fraction.
Export Options
About this article
Cite this article as:
Li Xia, Hu You-dong, Guo Yan, Chen Ying, Guo Dian-xuan, Zhou Hua-lan, Zhang Feng-lin and Zhao Qing-na, Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion, Current Pharmaceutical Design 2015; 21 (11) . https://dx.doi.org/10.2174/1381612821666141126100636
DOI https://dx.doi.org/10.2174/1381612821666141126100636 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Cardiac Nerves: A New Paradigm in The Management of Sudden Cardiac Death?
Current Medicinal Chemistry Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Modulation of Cardiac and Hepatic Cytochrome P450 Enzymes During Heart Failure
Current Drug Metabolism A Single Pill to Treat Postmenopausal Hypertension? Not Yet
Current Topics in Medicinal Chemistry Chemistry and Biological Activities of Buxus Alkaloids
Current Bioactive Compounds Cerebral Vascular Aging: Extending the Concept of Pulse Wave Encephalopathy Through Capillaries to the Cerebral Veins
Current Aging Science Midkine in Inflammatory and Toxic Conditions
Current Drug Delivery Potentiating the Naturally Occurring Process for Repair of Damaged Heart
Current Pharmaceutical Design Innate Immunity and the Heart
Current Pharmaceutical Design Peptides in Oral Diseases
Current Pharmaceutical Design Vascular effects of flavonoids
Current Medicinal Chemistry Neurovascular Complications of Ovarian Hyperstimulation Syndrome (OHSS): From Pathophysiology to Recent Treatment Options
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?
Current Enzyme Inhibition Modulation of Cardiovascular Function by Adipokines
Cardiovascular & Hematological Disorders-Drug Targets New Targets for Anticoagulation and Future Perspectives
Current Drug Discovery Technologies Effects of Ranolazine on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery Hybrid Stress Testing by Adenosine Infusion and Exercise Myocardial Perfusion Imaging: A Critical Appraisal
Current Cardiology Reviews Cardioprotective Effects of Sour Cherry Seed Extract (SCSE) on the Hypercholesterolemic Rabbit Heart
Current Pharmaceutical Design Proteomics to Identify Novel Biomarkers and Therapeutic Targets in Cardiovascular Disease
Letters in Drug Design & Discovery The Pathophysiology of Uric Acid in Relation to Cardiovascular Disease
Current Cardiology Reviews